We know great work begins with great people. Our skilled international team has a breadth of experience in life sciences, disease biology, biotechnology, and clinical in vitro diagnostics and is dedicated to supporting the medical community and helping improve patient care. It’s challenging work, but together we strive every day for improving the health of people worldwide and the sustained growth of the company.
Jörg Menten has a long-standing track record of leadership positions in the global health care industry. With an MBA of University of Mannheim, he spent the first half of his career with Boehringer Mannheim. As CFO of the Boehringer Mannheim Group he took a significant role in its acquisition through Roche AG in 1998. Since then, he served as President International for 2 companies headquartered in San Antonio TX – Kinetic Concepts (wound care) and CeloNova (liver cancer drug delivery), as well as CEO of Vanguard AG / Berlin (hospital services).
Dr. Moesslang has more than 25 years of global healthcare and finance leadership experience. Prior to joining SphingoTec he served as CEO of a US-based medical device and biotechnology start-up and held various executive roles with the Fresenius Group in Europe, Asia, and the US, most recently CFO of Fresenius Medical Care North America.
He holds a Doctor of Business Administration from University of Stuttgart-Hohenheim and a Master of Economics degree from Ludwig-Maximilians-University, Munich (Germany), and was trained at INSEAD and Harvard Business School.
Dr. Andreas Bergmann is a serial entrepreneur having founded and co-founded more than 10 companies. He has been active in the biotechnology industry for over 25 years and has been leading the discovery, and routine adoption of important blood biomarkers, as well as the development of drug candidates for critical care diseases. Today´s diagnostic standard in sepsis, Procalcitonin (PCT), was developed under his supervision as Chief Research Officer and co-founder at B.R.A.H.M.S AG. The company was successfully sold to Thermo Fisher Scientific Inc. for 480 USD in 2009.
Dr. Andreas Bergmann holds a PhD in Biochemistry from the Technical University Berlin. He is an inventor or co-inventor of more than 100 Patent families and has authored and co-authored over 200 peer-reviewed scientific publications. Dr. Bergmann is also member of the Executive Board of the “Waltraut Bergmann Stiftung zur Förderung der Krebsforschung” and a member of the Board of Trustees at “Sepsis Stiftung”.
Dr. Möller has over 40 years’ experience in the pharmaceutical and diagnostics industry. He held several senior management positions at Boehringer Mannheim, including CEO of the worldwide operating Group. Following the company’s acquisition by Roche, Dr. Möller was named Head of Global Development and Strategic Marketing Pharmaceuticals, and a member of Roche’s Executive Committee.
He has been an investment advisor at HBM Partners for 12 years and an active board member of many innovative life science companies such as Illumina Inc, B.R.A.H.M.S. AG, MTM Laboratories AG and Morphosys AG. From 2003 to 2016, Dr. Moeller served as Chairman of FIND (Foundation for Innovative New Diagnostics), a product development and implementation partnership financed by the Bill and Melinda Gates Foundation.
Dr. Ute Kilger is licensed as a German and European patent attorney and is assisting pharmaceutical and biotechnology companies as well as academic institutes in all kinds of patent related issues concerning the obtaining and enforcement of property rights, due diligence, mergers and acquisitions, contract negotiations, and licensing agreements.
Her counseling is driven by the understanding that a patent strategy has to add value to the company. She manages large patent portfolios in view of the business strategies as well as the cost-benefit analysis. She is involved in patent infringement processes where she is representing her clients in nullity suits up to the German Federal Supreme Court of Justice. Furthermore, Dr. Ute Kilger is a lecturer for the MBA BioMed course “Intellectual Property” (IP) at the University of Potsdam, as well as for the SPARK educational program of the Charité-Universitätsmedizin Berlin and for the IP Management and Contract Laws at the HTW in Berlin. Moreover, she is giving courses in the Charité program. Best Lawyers 2016 is counting her as one of the most important patent attorneys in the field of biotechnology in Germany. Since August 2009, she has been working as a partner of BOEHMERT & BOEHMERT.
Dr. Matthias Fehr has over twenty years of experience in private and public equity investment management and research. He served as senior sell-side analyst at Lombard Odier for biotech and medical technology industries and he is a former scientist at the Swiss Federal Institute of Technology. Dr. Fehr holds a MSc and PhD in chemistry from ETH Zurich and he is a Chartered Financial Analyst since 2002. Currently, he is a board member of Swixx Biopharma, Sphingotec, Numab and Farmalatam.